Incyte
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.
INCY Key Statistics
Stock Snapshot
As of today, Incyte(INCY) shares are valued at $106.91. The company's market cap stands at 20.98B, with a P/E ratio of 17.93.
On 2026-01-11, Incyte(INCY) stock moved within a range of $105.91 to $108.00. With shares now at $106.91, the stock is trading +0.9% above its intraday low and -1.0% below the session's peak.
Trading volume for Incyte(INCY) stock has reached 1.52M, versus its average volume of 2.14M.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.
INCY News
Stock Spotlight This Biotech Stock Eyes Fresh Entry With 522% Earnings Growth Seen Licensing Medicine remains one of the most potentially rewarding of all inves...
Incyte (INCY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Incyte’s Povorcitinib Trial Marks Progress in Treating Painf...
New insider activity at Incyte ( (INCY) ) has taken place on January 8, 2026. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing...
Analyst ratings
46%
of 28 ratingsMore INCY News
It's time once again for the Market Cap Game Show Holiday Edition, where intuition meets valuation and everyday life meets market caps. The Motley Fool's Bill...
If you are wondering whether Incyte shares still offer value at current levels, you are not alone. This article is designed to walk you through that question st...
Incyte (INCY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...
Incyte Corporation (NASDAQ:INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-lin...
In early January 2026, Incyte reported positive topline Phase 3 frontMIND results showing that adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP i...
William Blair analyst Matt Phipps has maintained their neutral stance on INCY stock, giving a Hold rating on December 24. Claim 70% Off TipRanks This Holiday Se...
Stock futures are showing modest gains as the first full trading week of 2026. Energy and defense stocks have been among the early leaders after a dramatic week...